✦ LIBER ✦

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

✍ Scribed by Marc A. Pfeffer; Emmanuel A. Burdmann; Chao-Yin Chen; Mark E. Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Peter Ivanovich; Reshma Kewalramani; Andrew S. Levey; Eldrin F. Lewis; Janet McGill; John J.V. McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K. Singh; Scott D. Solomon; Robert Toto; Hajime Uno

Book ID: 114469296
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 287 KB
Volume: 54
Category: Article
ISSN: 0272-6386
DOI: 10.1053/j.ajkd.2009.04.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale—Trial to Reduce Cardiovascular

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

✍ T.-Christian H. Mix; Robert M. Brenner; Mark E. Cooper; Dick de Zeeuw; Peter Iva 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Predictors of fatal and nonfatal cardiov

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

✍ John J.V. McMurray; Hajime Uno; Petr Jarolim; Akshay S. Desai; Dick de Zeeuw; Ka 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 463 KB

The Diabetes Subgroup Baseline Character

The Diabetes Subgroup Baseline Characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trial

✍ George Bakris; Allen Hester; Michael Weber; Bjorn Dahlof; Bert Pitt; Eric Velasq 📂 Article 📅 2008 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 236 KB

INTENSIVE ATORVASTATIN THERAPY REDUCES R

INTENSIVE ATORVASTATIN THERAPY REDUCES RISK OF CARDIOVASCULAR EVENTS BEYOND THE FIRST EVENT IN PATIENTS WITH MULTIPLE EVENTS

✍ Tikkanen, M.J.; Cater, N.B.; Holme, I.; Fayyad, R.; Faergeman, O.; Kastelein, J. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Baseline characteristics of menopausal w

Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene

✍ Nanette K. Wenger; Mary Jane Geiger 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Hormone replacement therapy did not redu

Hormone replacement therapy did not reduce the risk of cardiovascular events or non-cardiovascular disease outcomes in postmeopause women with CHD

📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 74 KB